Regenxbio Inc RGNX eyes pivotal sura-vec data this quarter and a Q1 2027 Bla filing for Rgx-202, backed by 251 million in cash and runway into late 2027.
Why Is Regenxbio Inc. (RGNX) Stock Down Today?
Updated Nov 16, 2026 8:30 PM ET · Prev Close $7.64
Primary Move Catalyst & Conviction
65% Signal ConvictionBiotechnology & Biological Products sector moving together
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 3.2% on average.
Market & Sector Relative Strength
RGNX trading in line with the S&P 500 (-0.34% alpha)Options Flow & Execution Desk
Bullish Flow · P/C 0.4Recent RGNX Catalyst Headlines
Verified WireRegenxbio Nasdaq Rgnx is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company s third-quart
Royalty declines and a litigation gain shaped the quarter's results.
Regenxbio RGNX delivered earnings and revenue surprises of 54.07 and -4.53 , respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for breakdown below $7.47
Technical Regime (RGNX)
MIXED MA TREND1-Year Historical Move Analogs
64 EventsSessions in the past year where RGNX moved >3.0% down:
Retail & Crowd Sentiment
NeutralBearish sentiment on $RGNX is growing as the company's expenses outpace revenues according to a StockTwits user.
About Regenxbio Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), ...
Get Instant RGNX Catalyst Alerts
Receive an email alert when RGNX triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversRGNX Session & Catalyst FAQ
Why is RGNX stock down today?
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 3.2% on average.
Is RGNX stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.32x relative volume (low participation). Our multi-factor model currently rates RGNX as HOLD. Review full valuation, quality, and timing signals on the RGNX Buy or Sell Decision Brief →
What is RGNX's intrinsic value and expected trading range?
At $7.47, RGNX's modeled 1-to-3 session range is $7.25 – $7.62, with a key inflection level at $7.10 (support). Compare current price against multi-year cash flow projections in the RGNX Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for RGNX?
RSI at 48.3 reflects soft below-midline momentum. RGNX trades at $7.47 relative to its 20-day SMA ($7.42) and 50-day SMA ($7.63), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.